Skip to main content

Table 1 Baseline characteristics of patients in the control and exenatide groups

From: Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial

  Control group (n = 43) Exenatide group (n = 49) Standardized difference
Age (years) 69 [61–76] 71 [63–75] − 0.26
Malesa 36 (84%) 46 (94%) − 0.33
ASA physical status IIIa 41 (95%) 46 (94%) 0.06
Comorbitiesa
 Smoking 21 (49%) 28 (57%) − 0.17
 Hypertension 30 (70%) 29 (59%) 0.22
 Dyslipidemia 25 (58%) 30 (61%) − 0.06
 Obesity (BMI ≥ 30 kg m−2) 10 (23%) 7 (14%) 0.23
 Diabetes mellitus 9 (21%) 10 (20%) 0.01
Creatinine clearance (ml min−1) 82 [74–93] 82 [75–90] 0.02
Fasting blood glucose (mg dl−1) 105 [99–115] 101 [94–112] 0.23
Glycated hemoglobin (%) 5.7 [5.5–6.1] 6.0 [5.6–6.3] − 0.33
Euroscore 4.8 [3.5–7.3] 5.4 [4.6–7.3] − 0.07
Left ventricular ejection fraction (%)a
 < 30 0 (0%) 1 (2%)  
 30–50 6 (14%) 15 (31%)  
 > 50 37 (86%) 33 (67%)  
Surgical procedure
 Number of bypass grafts 3 [2–4] 3 [2–4] − 0.30
 Duration of surgery (min)b 237 (58) 251 (58) − 0.24
 On-pump surgery 29 (67%) 33 (67%) 0.00
 Duration of ECC (min)a 67 [53–84] 71 [59–91] − 0.23
 Duration of aortic cross clamping (min)a 61 [46–89] 63 [52–79] 0.16
Maintenance of anesthesia
 Sevofluranea 8 (19) 11 (22) 0.80
 Propofola 14 (32) 16 (33) 1.00
 Propofol and sevofluranea,c 21 (49) 22 (45) 0.83
  1. Data are median [interquartile range 25–75%]
  2. ASA American Society of Anesthesiologists, BMI body mass index, ECC extracorporeal circulation
  3. aData are number of patients (percentage)
  4. bData are mean (standard deviation)
  5. cGeneral anesthesia was maintained with inhalation of sevoflurane until the start of cardiopulmonary bypass; then, the inhalation of sevoflurane was definitely stopped and target-controlled infusion of propofol was started and was proceeded until the end of general anesthesia